Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

Learn how Novartis is working with chronic obstructive pulmonary disease (COPD) patients to develop digital health technologies that help them find their “new normal.”

Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR) and Vas Narasimhan, Head of Global Drug Development and Chief Medical Officer, share their outlook for innovation in 2017.

Volunteerism and giving back to communities where we live and work are more than just tradition; they’re core values.